MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 Skipping
Open Access
- 17 August 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 26 (12) , e2297-e2301
Abstract
Comprehensive genetic profiling using next-generation sequencing technologies has become an integral part of precision oncology. Variant annotation requires translating the DNA findings into protein level predictions. In this article we highlight inconsistencies in variant annotation for the MET D1228N exon 19 resistance mutations. MET D1228N and D1246N represent the same resistance mutation in MET exon 14 skipping alterations annotated on different transcripts. Additional examples of relevant variants annotated on different transcripts emphasize the importance of avoiding erroneous interpretation when realizing precision oncology.Keywords
Funding Information
- National Institutes of Health (R37CA225655)
This publication has 17 references indexed in Scilit:
- Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical ModelsClinical Cancer Research, 2017
- Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung CancerClinical Cancer Research, 2017
- Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternationsLung Cancer, 2016
- Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 SkippingJournal of Thoracic Oncology, 2016
- MET Exon 14 Skipping in Non-Small Cell Lung CancerThe Oncologist, 2016
- The epidermal growth factor receptor variant III (EGFRvIII): where wild things are alteredThe FEBS Journal, 2013
- A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer PatientsCancer Research, 2011
- Gain of function mutations of RTK conserved residues display differential effects on NTRK1 kinase activityOncogene, 2002
- Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies.Proteins: Structure, Function, and Bioinformatics, 2001
- Amino-acid Sequence of Slightly Lysine-rich HistoneNature, 1970